跳到正文
cccskills
免费在 GitHub 公开

es-cushing-treat-specific-comorbidities-lifelong

This skill directs lifelong treatment of cardiovascular risk factors, osteoporosis, and psychiatric symptoms in all patients with Cushing's syndrome until biochemical resolution of hypercortisolism. Use when managing any CS patient for long‑term comorbidity control; triggers include persistent hypertension, dyslipidemia, low bone density, depression, anxiety, or cognitive changes in the setting of known or suspected CS.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL

实测评分 未实测

查看安装方法

包含的文件（1）

  • SKILL.md2.7 KB

SKILL.md（原文）

安装前可以查看交给 AI 代理的指令内容。

Treating Specific Comorbidities Associated with Cushing's Syndrome Throughout Life Until Resolution

STEP 1 — Gather Information

Confirm diagnosis of Cushing's syndrome (elevated UFC, late‑night salivary cortisol, or dexamethasone suppression test) and assess remission status; document baseline cardiovascular risk factors (BP, lipids, smoking, diabetes), osteoporosis (DEXA T‑score, fracture history), and psychiatric symptoms (PHQ‑9, GAD‑7, cognitive screening).

STEP 2 — Rule In / Rule Out

If CS is not in remission (persistent hypercortisolism), treat comorbidities while pursuing definitive CS treatment; if CS is in remission, proceed to evaluate whether comorbidities require ongoing therapy.

STEP 3 — Classify or Stratify

Stratify each comorbidity: hypertension (stage 1/2), dyslipidemia (LDL‑C thresholds), osteoporosis (T‑score ≤‑1.0 osteopenia, ≤‑2.5 osteoporosis), psychiatric severity (PHQ‑9 ≥5 mild, ≥10 moderate, ≥15 severe).

STEP 4 — Decide

Initiate or continue guideline‑directed therapy for each abnormality (antihypertensives, statins, bone‑modifying agents, antidepressants or psychotherapy) and schedule reassessment of CS remission and comorbidity control every 3–6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not discontinue comorbidity treatment solely because cortisol normalizes; undertreating osteoporosis increases fracture risk; avoid overlooking psychiatric relapse; beware of glucocorticoid excess from overtreatment of adrenal insufficiency; monitor for drug‑drug interactions when using steroidogenesis inhibitors.

Concrete Clinical Example

A 48‑year‑old woman with Cushing’s disease postsurgical remission (normal UFC) presents with BP 152/94 mmHg, LDL 130 mg/dL, lumbar T‑score ‑2.8, and PHQ‑9 12. She is started on lisinopril, atorvastatin, oral bisphosphonate plus calcium/vitamin D, and sertraline; BP, lipids, BMD, and mood are rechecked at 3‑month intervals and continued lifelong until her CS remains resolved and comorbidities normalize.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

评价

还没有评价。欢迎分享你的使用感受。

评论

无需登录即可发表。欢迎分享使用感受、提问，或说明在哪些环境下无法运行。

还没有评论。来写第一条吧。

提交后会立即公开。请勿填写邮箱、电话等个人信息。URL 最多 2 个。

0 / 1000 字

此表单受 reCAPTCHA 保护，适用 Google 的隐私权政策和服务条款。

同一仓库的技能

780g-pump-adjustment

免费

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

ata-acth-stim-test-interpretation

免费

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

ata-adrenal-crisis-treatment

免费

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

ata-aed-ai-education

免费

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

ata-aed-lt4-monitoring

免费

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

ata-cortisol-cutoff-ai-diagnosis

免费

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

查看 dromlakhani 的全部技能

报告此技能的问题